Nuclidium presented positive data from the phase I clinical trial of its new copper-61 (Cu-61) PET imaging agent for prostate cancer at the SNMMI 2025 annual meeting.
Cu-61 NuriPro demonstrated a safety profile comparable to clinically established prostate-specific membrane antigen (PSMA) tracers with a favorable imaging performance in the phase I trial conducted with PSMA-positive metastatic prostate cancer patients at Hoag Molecular Imaging and Therapy Clinic in Newport Beach, CA, the company said.
In notable findings, Cu-61 NuriPro PET detected more lesions up to four hours after administration in 50% of the patients than F-18 piflufolastat PET, with the dosimetry data showing favorable tumor-to-background ratios. According to Nuclidium, Cu-61 NuriPro’s 3.3-hour half-life and high positron yield contributes to a greater distribution range and later imaging following administration.
Nuclidium noted that Cu-61 NuriPro is the diagnostic component of its PSMA-targeted NuriPro program. The company’s second diagnostic, Cu-61 TraceNET, which targets somatostatin receptor-positive tumors, is currently in a phase I/IIa clinical trial for broncho-pulmonary and gastroenterohepatic neuroendocrine tumors and will be developed further as a diagnostic for a subset of metastatic breast cancer patients.
The firm said that it expects to begin enrollment for clinical trials of two corresponding therapeutics, Cu-67 NuriPro and Cu-67 TraceNET, respectively, in early 2026.
